OncoCyte (NASDAQ:OCX - Get Free Report)'s stock had its "equal weight" rating restated by analysts at Stephens in a research report issued on Tuesday,Benzinga reports. They currently have a $4.00 target price on the stock. Stephens' target price indicates a potential upside of 24.61% from the stock's previous close.
Other equities analysts have also recently issued research reports about the stock. StockNews.com began coverage on shares of OncoCyte in a research report on Monday, January 13th. They set a "sell" rating for the company. Needham & Company LLC reissued a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $4.56.
Get Our Latest Stock Report on OncoCyte
OncoCyte Price Performance
OncoCyte stock traded down $0.01 during mid-day trading on Tuesday, reaching $3.21. The company had a trading volume of 36,749 shares, compared to its average volume of 65,135. The stock's 50-day simple moving average is $2.79 and its 200-day simple moving average is $2.73. The company has a market capitalization of $56.02 million, a P/E ratio of -0.73 and a beta of 0.79. OncoCyte has a 1 year low of $1.92 and a 1 year high of $4.75.
OncoCyte (NASDAQ:OCX - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.88. The firm had revenue of $1.49 million during the quarter, compared to the consensus estimate of $0.16 million. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. On average, equities analysts forecast that OncoCyte will post -2.57 EPS for the current fiscal year.
Insiders Place Their Bets
In other OncoCyte news, CFO Andrea S. James bought 97,561 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was purchased at an average cost of $2.05 per share, for a total transaction of $200,000.05. Following the completion of the purchase, the chief financial officer now owns 151,231 shares of the company's stock, valued at $310,023.55. This trade represents a 181.78 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Patrick W. Smith purchased 1,077,600 shares of the firm's stock in a transaction on Friday, February 7th. The stock was acquired at an average cost of $2.05 per share, for a total transaction of $2,209,080.00. Following the completion of the purchase, the insider now owns 2,872,671 shares in the company, valued at $5,888,975.55. The trade was a 60.03 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 1,185,625 shares of company stock valued at $2,430,510 in the last ninety days. Insiders own 1.58% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of OCX. Geode Capital Management LLC grew its holdings in OncoCyte by 12.2% in the third quarter. Geode Capital Management LLC now owns 103,980 shares of the company's stock valued at $296,000 after purchasing an additional 11,289 shares during the period. FNY Investment Advisers LLC grew its stake in shares of OncoCyte by 15.1% during the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company's stock valued at $117,000 after buying an additional 6,481 shares during the period. Wealthedge Investment Advisors LLC acquired a new stake in shares of OncoCyte during the 4th quarter worth $126,000. Ground Swell Capital LLC acquired a new stake in shares of OncoCyte during the 4th quarter worth $26,000. Finally, Broadwood Capital Inc. raised its position in shares of OncoCyte by 26.7% in the 4th quarter. Broadwood Capital Inc. now owns 6,244,405 shares of the company's stock worth $14,862,000 after buying an additional 1,315,339 shares during the period. Institutional investors and hedge funds own 55.35% of the company's stock.
About OncoCyte
(
Get Free Report)
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Read More
Before you consider OncoCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OncoCyte wasn't on the list.
While OncoCyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
